Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02538146
Other study ID # UKentucky
Secondary ID
Status Terminated
Phase Early Phase 1
First received August 26, 2015
Last updated March 7, 2017
Start date August 2015
Est. completion date October 2016

Study information

Verified date March 2017
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open label pilot study will determine the effect of the amino acid nutritional supplement acetyl-L-carnitine (ALC) on pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. The ALC is given to all participants for 3 months, and assessments will occur at intake and after 3 months.


Description:

This is an open label pilot study to determine the effect of the amino acid nutritional supplement acetyl-L-carnitine (ALC) on chronic pancreatitis. ALC is an acetylated form of naturally occurring amino acid L-carnitine ((R)-3-Acetyloxy-4-trimethylammonio-butanoate) found in red meat and is readily commercially available. Supplementation with ALC may decrease pain and improve overall health based on our preclinical treatment studies in rats with high fat and alcohol induced pancreatitis. In rats, ALC reduces pain measures, improves glucose tolerance, decreases lipid peroxidation, and Ki67 cellular injury biomarker, and improves pancreatic histopathology. The measurable outcomes of this clinical study are patients' questionnaire scores for:

pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. The questionnaires are given at intake and at experiment end (3 months). Participants will receive ALC for 3 months. These findings will indirectly determine the effect of ALC on the function and inflammatory state of the pancreas. Currently, there is no specific therapy for chronic pancreatitis, and its pathophysiology is still poorly understood. It is known that chronic pancreatitis is caused by ongoing inflammation in the pancreas, yet, no pharmacological intervention exists that optimally addresses this. The broad actions of ALC as an antioxidant and anti-inflammatory agent as well as its ability to reduce side-effects of alcohol cessation make it a perfect compound to pursue for the treatment of pancreatitis.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date October 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 20 Years to 90 Years
Eligibility Inclusion Criteria:

- Only patients with chronic pancreatitis are included.

Exclusion Criteria:

- Patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma,

- Females that are pregnant or lactating

- Children are excluded.

- Patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking ALC according to manufacturer.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
acetyl-L-carnitine 1000mg 2X per day for 3 months
non-essential dietary amino acid

Locations

Country Name City State
United States University of Kentucky Center for Clinical and Translational Science Lexington Kentucky

Sponsors (2)

Lead Sponsor Collaborator
Karin High University of Kentucky

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain score McGill short form Visual Analogue Scale (VAS scale) 1 normal 2-10 pain level 3 months
Secondary Well Being Normal: 0 of 30 days with major impairment; 30 of 30 days feeling very healthy and full of energy 3 months
Secondary Generalized anxiety disorder 7-item (GAD-7) Scoring 5-< 10 Mild Anxiety 10-<15 Moderate Anxiety >15 Severe Anxiety 5-< 10 Mild Anxiety 10-<15 Moderate Anxiety >15 Severe Anxiety 5-< 10 Mild Anxiety 10-<15 Moderate Anxiety >15 Severe Anxiety 5-< 10 Mild Anxiety; 10-<15 Moderate Anxiety; >15 Severe Anxiety 3 months
Secondary Patient Depression Questionnaire Scoring 5-<10 Mild Depression; 10-<15 Moderate Depression; 15-<20 Moderately Severe Depression; >20 Severe Depression 3 months
Secondary Inflammatory Markers TBARS: in fasted (8 hrs) 4.7±0.2 µmol/l blood serum; TGFbeta1: 20-50 pg/ml; PDGF: 20-30 pg/ml 3 months
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting NCT06068426 - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3